
Michael J Goodheart

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8855798/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain, Behavior, and Immunity, 2011, 25, 250-255.	2.0	159
2	Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain, Behavior, and Immunity, 2009, 23, 176-183.	2.0	145
3	Social Influences on Clinical Outcomes of Patients With Ovarian Cancer. Journal of Clinical Oncology, 2012, 30, 2885-2890.	0.8	142
4	Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer, 2003, 98, 2199-2206.	2.0	100
5	Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer, 2013, 119, 3234-3241.	2.0	92
6	Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability. Brain, Behavior, and Immunity, 2013, 30, S126-S134.	2.0	89
7	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecologic Oncology, 2017, 146, 484-490.	0.6	81
8	Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain, Behavior, and Immunity, 2012, 26, 1037-1044.	2.0	77
9	Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology, 2015, 53, 256-267.	1.3	76
10	Intra-operative frozen section results reliably predict final pathology in endometrial cancer. Gynecologic Oncology, 2014, 133, 499-505.	0.6	68
11	Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain, Behavior, and Immunity, 2010, 24, 1231-1240.	2.0	67
12	The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer. Clinical Cancer Research, 2005, 11, 3733-3742.	3.2	66
13	TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. International Journal of Oncology, 2015, 46, 607-618.	1.4	62
14	<i>Sox2</i> and <i>Lef-1</i> interact with <i>Pitx2</i> to regulate incisor development and stem cell renewal. Development (Cambridge), 2016, 143, 4115-4126.	1.2	58
15	Wnt3a regulates Lef-1 expression during airway submucosal gland morphogenesis. Developmental Biology, 2007, 305, 90-102.	0.9	52
16	Endometrial Cancer. Obstetrics and Gynecology Clinics of North America, 2012, 39, 255-268.	0.7	50
17	Robotic surgery in supermorbidly obese patients with endometrial cancer. American Journal of Obstetrics and Gynecology, 2015, 213, 49.e1-49.e8.	0.7	50
18	microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncology Reports, 2011, 26, 995-1002.	1.2	45

Michael J Goodheart

#	Article	IF	CITATIONS
19	Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecologic Oncology, 2005, 96, 470-474.	0.6	44
20	Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers. Current Oncology Reports, 2012, 14, 277-284.	1.8	44
21	The Effect of Improving Basic Preventive Measures in the Perioperative Arena on <i>Staphylococcus aureus</i> Transmission and Surgical Site Infections. JAMA Network Open, 2020, 3, e201934.	2.8	41
22	The influence of microvessel density on ovarian carcinogenesis. Gynecologic Oncology, 2003, 90, 566-571.	0.6	40
23	CGRP induction in cystic fibrosis airways alters the submucosal gland progenitor cell niche in mice. Journal of Clinical Investigation, 2011, 121, 3144-3158.	3.9	40
24	A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 2014, 132, 526-530.	0.6	40
25	Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer. Psychoneuroendocrinology, 2017, 84, 139-142.	1.3	39
26	Wnt Signaling Regulates Airway Epithelial Stem Cells in Adult Murine Submucosal Glands. Stem Cells, 2016, 34, 2758-2771.	1.4	37
27	Ovarian Cancer p53 Mutation Is Associated with Tumor Microvessel Density. Gynecologic Oncology, 2002, 86, 85-90.	0.6	36
28	The Role of LEF1 in Endometrial Gland Formation and Carcinogenesis. PLoS ONE, 2012, 7, e40312.	1.1	36
29	MicroRNA-26b Represses Colon Cancer Cell Proliferation by Inhibiting Lymphoid Enhancer Factor 1 Expression. Molecular Cancer Therapeutics, 2014, 13, 1942-1951.	1.9	33
30	Prediction of chemo-response in serous ovarian cancer. Molecular Cancer, 2016, 15, 66.	7.9	33
31	p21 expression predicts outcome in p53-null ovarian carcinoma. Clinical Cancer Research, 2003, 9, 1028-32.	3.2	32
32	Selective suppression of cervical cancer Hela cells by 2-O-β-d-glucopyranosyl-l-ascorbic acid isolated from the fruit of Lycium barbarum L Cell Biology and Toxicology, 2011, 27, 107-121.	2.4	31
33	Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. International Journal of Gynecological Cancer, 2020, 30, 845-852.	1.2	29
34	Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. Cancer, 2018, 124, 580-586.	2.0	27
35	Sox17 modulates Wnt3A∫î²-catenin-mediated transcriptional activation of the Lef-1 promoter. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2010, 299, L694-L710.	1.3	26
36	Conditional deletion of Sox17 reveals complex effects on uterine adenogenesis and function. Developmental Biology, 2016, 414, 219-227.	0.9	26

MICHAEL J GOODHEART

#	Article	IF	CITATIONS
37	SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget, 2016, 7, 33179-33191.	0.8	26
38	Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients. Gynecologic Oncology, 2013, 131, 667-673.	0.6	23
39	Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer, 2018, 124, 3401-3408.	2.0	23
40	Sox2 modulates Lef-1 expression during airway submucosal gland development. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L645-L660.	1.3	22
41	Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182. Oncology Reports, 2016, 35, 2461-2465.	1.2	22
42	Changes in spiritual wellâ€being and psychological outcomes in ovarian cancer survivors. Psycho-Oncology, 2018, 27, 477-483.	1.0	22
43	Thromboembolic events in patients with cervical carcinoma: Incidence and effect on survival. Gynecologic Oncology, 2009, 113, 240-244.	0.6	20
44	Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma. Experimental and Therapeutic Medicine, 2012, 3, 677-682.	0.8	19
45	Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer. Cancer Letters, 2013, 331, 99-104.	3.2	19
46	Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Gynecologic Oncology, 2016, 140, 152-160.	0.6	18
47	<p>An integrated prediction model of recurrence in endometrial endometrioid cancers</p> . Cancer Management and Research, 2019, Volume 11, 5301-5315.	0.9	17
48	Rural residence is related to shorter survival in epithelial ovarian cancer patients. Gynecologic Oncology, 2021, 163, 22-28.	0.6	16
49	Eudaimonic wellâ€being and tumor norepinephrine in patients with epithelial ovarian cancer. Cancer, 2015, 121, 3543-3550.	2.0	15
50	Epithelialâ€mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. Cancer, 2020, 126, 4407-4413.	2.0	15
51	Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. Psychoneuroendocrinology, 2019, 106, 244-251.	1.3	14
52	Placenta-Specific Protein 1: A Potential Key to Many Oncofetal-Placental OB/GYN Research Questions. Obstetrics and Gynecology International, 2014, 2014, 1-5.	0.5	13
53	What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer, 2017, 123, 985-993.	2.0	13
54	Creation and validation of models to predict response to primary treatment in serous ovarian cancer. Scientific Reports, 2021, 11, 5957.	1.6	13

MICHAEL J GOODHEART

#	Article	IF	CITATIONS
55	Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. Scientific Reports, 2021, 11, 11595.	1.6	13
56	p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. International Journal of Oncology, 2017, 50, 1721-1728.	1.4	12
57	A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables. International Journal of Molecular Sciences, 2019, 20, 1205.	1.8	12
58	Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 1175.	1.8	11
59	Intraoperative autologous blood transfusion use during radical hysterectomy for cervical cancer: long-term follow-up of a prospective trial. Archives of Gynecology and Obstetrics, 2012, 286, 717-721.	0.8	10
60	Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma. Archives of Gynecology and Obstetrics, 2009, 280, 675-678.	0.8	9
61	Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18–Positive Cervical Cancers Is Associated With Tumor Histology. International Journal of Gynecological Cancer, 2017, 27, 784-790.	1.2	9
62	The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients. Gynecologic Oncology, 2015, 138, 154-158.	0.6	8
63	A Single-Institution Evaluation of Factors Important in Fallopian Tube Carcinoma Recurrence and Survival. International Journal of Gynecological Cancer, 2011, 21, 1.	1.2	7
64	Uterine Clostridium perfringens infection related to gynecologic malignancy. Gynecologic Oncology Reports, 2017, 22, 55-57.	0.3	7
65	Identification of Novel IncRNAs in Ovarian Cancer and Their Impact on Overall Survival. International Journal of Molecular Sciences, 2021, 22, 1079.	1.8	7
66	Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome. Cancers, 2021, 13, 1109.	1.7	7
67	Disparity of ovarian cancer survival between urban and rural settings. International Journal of Gynecological Cancer, 2022, 32, 540-546.	1.2	7
68	Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations. Gynecologic Oncology, 2016, 142, 150-157.	0.6	6
69	Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA. International Journal of Molecular Sciences, 2019, 20, 1192.	1.8	6
70	Gynecologic Oncology: Challenges of Minimally Invasive Surgery In a Field of Maximal Complexities. Clinical Obstetrics and Gynecology, 2020, 63, 30-39.	0.6	5
71	Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 4791.	1.8	4
72	Chronic difficulties are associated with poorer psychosocial functioning in the first year postâ€diagnosis in epithelial ovarian cancer patients. Psycho-Oncology, 2021, 30, 954-961.	1.0	4

MICHAEL J GOODHEART

#	Article	IF	CITATIONS
73	Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment. Psychosomatic Medicine, 2021, 83, 417-422.	1.3	4
74	Intestinal lymphangiectasia mimicking primary peritoneal carcinoma. American Journal of Obstetrics and Gynecology, 2010, 203, e9-e11.	0.7	3
75	Malignant struma ovarii with insular carcinoma: A case report and literature review. Gynecologic Oncology Reports, 2016, 18, 1-3.	0.3	3
76	Alterations of Vascular Endothelial Growth Factor A Expression and Microvessel Density Associated With Polypropylene Vaginal Mesh. Female Pelvic Medicine and Reconstructive Surgery, 2020, 26, 73-79.	0.6	1
77	BRCA1 and BRCA2 alterations in ovarian MMMT. Gynecologic Oncology, 2004, 95, 774.	0.6	0
78	Staging Endometrial Cancer. CRSLS MIS Case Reports From SLS, 2014, 18, .	0.2	0
79	Primary radiation as initial management in endometrial cancer. Proceedings in Obstetrics and Gynecology, 2020, 9, 14.	0.1	Ο